三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

已收盘 08-14 16:08:36

17.530

-0.250

-1.41%

最高17.980	最低17.390	成交量1,889万
今开17.780	昨收17.780	日振幅3.32%
总市值443.51亿	流通市值443.51亿	总股本25.30亿
成交额3.33亿	换手率0.75%	流通股本25.30亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":17.53,"timestamp":1786694916003,"preClose":17.78,"halted":0,"volume":18890985,"delay":0,"changeRate":-0.014060742407199098,"floatShares":2530000000,"shares":2530000000,"eps":3.9920890193278047,"marketStatus":"已收盘","change":-0.25,"latestTime":"08-14 16:08:36","open":17.78,"high":17.98,"low":17.39,"amount":332922795,"amplitude":0.033183,"askPrice":17.53,"askSize":14000,"bidPrice":17.51,"bidSize":500,"shortable":3,"etf":0,"ttmEps":3.9929118784930124,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":17.78,"dividendRate":0.014912,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.788505,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","LU0348783233.USD","LU0417516571.SGD","LU0561508036.HKD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU1303224171.USD","02196","BK1191","LU1770034418.SGD","LU0828237510.HKD","LU0634319403.HKD","LU2778985437.USD","QTOC","02268","LU0348827113.USD","LU0348784397.USD","LU0640798160.USD","BK1500","LU1961090484.USD","BK1585","LU2476274720.SGD","VTHR","ARTY","03933","KCE","LU0417516738.SGD","02367","SG9999004311.SGD","LU2328871848.SGD","BK1515","06160","KURE","AGIX","02228","01530","CHAT","LU0348766576.USD","LU2476274308.USD","09926","01099","06821","BK1197","LU1719994722.HKD","AIPO","601066","LU0348825331.USD","LU0348735423.USD","01477","01789"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181197799","title":"财报前瞻｜三生制药本季度预测数据缺失，机构观点待统一","url":"https://stock-news.laohu8.com/highlight/detail?id=1181197799","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181197799?lang=zh_cn&edition=full","pubTime":"2026-08-13 08:28","pubTimestamp":1786580881,"startTime":"0","endTime":"0","summary":"三生制药将于2026年08月20日发布最新季度财报，市场正在关注盈利质量与主营结构的延续性表现。由于缺乏可用与合规口径的一致预期数据，本季度关于三生制药的营收、毛利率、净利润或净利率、调整后每股收益的具体预测以及同比信息暂未取得。公司业务与财务方面的关键看点在于高毛利率水平下的盈利弹性与费用管控。若本季度新品或新增适应症放量，毛利率有望维持在高位，费用侧的学术推广与渠道投入将决定利润释放节奏。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜三生制药本季度预测数据缺失，机构观点待统一","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112685212","title":"异动解读｜三生制药盘中上涨5.18%，中期业绩审议在即叠加辉瑞重磅BD持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1112685212","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112685212?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:47","pubTimestamp":1786326467,"startTime":"0","endTime":"0","summary":"8月10日，三生制药盘中上涨5.18%，报18.93港元，成交额1.08亿港元。消息面上，公司于8月7日公告将于8月20日召开董事会审议中期业绩并考虑派发中期股息，市场对业绩兑现及分红预期升温。此外，招银国际近期将三生制药列为创新药行业首推标的，板块整体延续修复行情，荣昌生物涨5.10%、康方生物涨3.80%，行业共振进一步支撑个股表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172286345","title":"三生制药(01530)拟于2026年8月20日召开董事会审议中期业绩及股息分派","url":"https://stock-news.laohu8.com/highlight/detail?id=1172286345","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172286345?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:41","pubTimestamp":1786092081,"startTime":"0","endTime":"0","summary":"三生制药(01530)7日发布董事会会议通告称，公司董事会将于2026年8月20日（星期四）召开会议，审议并批准刊发集团截至2026年6月30日止六个月的未经审核中期业绩，并考虑派发中期股息（如有）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133891417","title":"三生制药更新7月股份变动月报表，新增155,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1133891417","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133891417?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:37","pubTimestamp":1785832646,"startTime":"0","endTime":"0","summary":"三生制药于2026年8月4日发布了2026年7月股份变动月报表，披露公司在报告期内注册股本保持50,000,000,000股不变，同时当月新增发行155,000股普通股。上述新增发行的155,000股来自购股权计划的行权所致，对应行权价为每股7.62港元，本月至少共获得1,181,100港元的资金。期权行权后，该部分购股权余量由10,287,500股减少至10,132,500股。截至2026年7月31日，三生制药已有发行股份总数为2,538,239,412股，公司股本规模持续增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","09939","02268","LU0588546209.SGD","LU2039709279.SGD","03692","03329","BK1587","09996","06990","01530","02096","LU0348783233.USD","LU0196878994.USD","LU0417516571.SGD","02273","LU0572944931.SGD","01548","KURE","01276","LU1720050803.USD","BK1521","03759","LU2476274308.USD","LU0634319403.HKD","LU2097828714.EUR","02269","06160","HK0000320223.HKD","LU1880383366.USD","LU2328871848.SGD","09926","01177","01952","LU1813983027.USD","02596","LU0856984785.SGD","01951","HK0000165453.HKD","LU2399975544.HKD","01801","KCE","06821","06996","09966","02162","01093","06078","BK1219","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653716228","title":"大行评级｜招银国际：创新药行业的基本面强劲，首推三生制药、信达生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2653716228","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653716228?lang=zh_cn&edition=full","pubTime":"2026-07-23 13:39","pubTimestamp":1784785161,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01801","LU2242644610.SGD","LU2488822045.USD","KURE","LU2097828805.USD","LU1969619763.USD","BK1589","LU2097828557.USD","LU2097828631.EUR","HK0000165453.HKD","BK1161","LU0502904849.HKD","BK1574","LU2097828474.EUR","BK1583","01530","BK1593","LU0455707207.USD","06978","LU2097828714.EUR","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU0348827113.USD","LU0359201612.USD","KURE","01530","LU2399975544.HKD","VXUS","BK1576","BK1588","LU0516422440.USD","LU0043850808.USD","01276","LU0979878070.USD","LU0196878994.USD","KCAI","LU1242518931.SGD","LU1720050803.USD","SG9999002463.SGD","01093","LU1242518857.USD","06160","LU2328871848.SGD","159992","HK0000165453.HKD","02269","LU0708995583.HKD","06978","LU0327786744.USD","LU0417516738.SGD","688331","BK4585","IE00BZ08YT58.USD","BK1593","09926","01672","LU1226288170.HKD","LU0516422366.SGD","LU1064130708.USD","06990","09995","01801","BK0239","IBBQ","LU0052750758.USD","LU1951186391.HKD","LU2097828474.EUR","02268","MEDX","02162","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193381924","title":"异动解读｜三生制药盘中上涨5.51%，生物科技板块集体走强叠加超跌修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1193381924","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193381924?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:14","pubTimestamp":1784513659,"startTime":"0","endTime":"0","summary":"7月20日，三生制药盘中上涨5.51%，报17.04港元/股，成交额1.59亿港元。消息面上，生物科技板块集体走强，荣昌生物涨8.13%、科伦博泰生物涨7.63%、康方生物涨6.51%、信达生物涨5.06%、百济神州涨4.2%，板块联动效应显著。此外，三生制药此前因东方证券减持613.1万股引发7月17日单日大跌9.83%，短期存在超跌修复需求。三生制药是一家主要从事生物制药产品开发、生产及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，同时从事CDMO业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652479358","title":"三生制药(01530)下挫9.77% 遭东方证券减持613.1万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652479358","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652479358?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:32","pubTimestamp":1784255524,"startTime":"0","endTime":"0","summary":"金吾财讯 | 三生制药(01530)盘中下挫9.77%，最新报16.16港元，成交额4.62亿港元。消息面上，港交所文件显示，东方证券已于7月10日减持三生制药613.1万股，每股作价17.8677港元，总金额约1.1亿港元。减持后东方证券持股数目约为1.77亿股，持股比例为6.97%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986120","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1564","BK1147","BK1161","BK1593","01530","600958","BK0183","BK0188","BK0012","BK0028","BK0276","HK0000165453.HKD","03958","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163099933","title":"异动解读｜三生制药盘中下跌5.64%，机构减持叠加生物科技板块回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1163099933","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163099933?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:08","pubTimestamp":1784254091,"startTime":"0","endTime":"0","summary":"7月17日，三生制药盘中下跌5.64%，报16.45港元/股，成交额3.43亿港元。消息面上，东方证券于7月10日减持三生制药613.1万股，每股作价约17.87港元，总金额约1.1亿港元，减持后持股比例降至6.97%。机构接连减持对市场情绪形成压制。三生制药是一家主要从事生物制药产品开发、生产及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，同时从事CDMO业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651499914","title":"东方证券减持三生制药(01530.HK)613.1万股 每股作价约17.87港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651499914","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651499914?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:00","pubTimestamp":1784199627,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1564","01530","BK1583","BK1147","HK0000165453.HKD","03958","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","LU0417516902.SGD","KURE","LU0502904849.HKD","LU2476274308.USD","01801","LU2097828631.EUR","LU0348767384.USD","LU0540923850.HKD","LU0348827113.USD","LU0417516738.SGD","LU0348825331.USD","BK1583","LU2778985437.USD","09926","IE00BPRC5H50.USD","BK1574","IE00B543WZ88.USD","LU0348784397.USD","LU0455707207.USD","LU2097828714.EUR","02268","IBBQ","06990","LU0634319403.HKD","06978","02162","09995","LU2097828474.EUR","LU2399975544.HKD","BK1587","LU2097828805.USD","BK1589","MEDX","LU2488822045.USD","BK1161","BK1593","06855","01477","02157","01530","BK1191","LU0561508036.HKD","159992","LU1961090484.USD","SG9999014674.SGD","LU2328871848.SGD","LU2097828557.USD","LU0417516571.SGD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183211465","title":"异动解读｜三生制药盘中上涨5.64%，报18.37港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183211465","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183211465?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:52","pubTimestamp":1784080334,"startTime":"0","endTime":"0","summary":"7月15日，三生制药盘中上涨5.64%，报18.37港元/股，成交额1.49亿港元。三生制药所在的生物科技行业中，个股普遍走强，其中科伦博泰生物涨9.49%，康方生物涨7.04%，信达生物涨6.5%，派格生物医药-B涨5.69%，百济神州涨1.99%。三生制药是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，业务覆盖血小板减少症、慢性肾病贫血症、强直性脊柱炎等领域，同时从事CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651103132","title":"汇添富基金减持三生制药(01530.HK)613.1万股 每股作价约17.87港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651103132","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651103132?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:46","pubTimestamp":1784029619,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","BK1583","BK1593","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167855848","title":"异动解读｜三生制药盘中下跌5.49%，报17.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167855848","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167855848?lang=zh_cn&edition=full","pubTime":"2026-07-14 09:59","pubTimestamp":1783994390,"startTime":"0","endTime":"0","summary":"7月14日，三生制药盘中下跌5.49%，报17.06港元/股，成交额1.77亿港元。三生制药所在的生物科技行业中，个股普遍走弱，其中信达生物跌0.39%，百济神州跌0.75%，康方生物跌1.42%，科伦博泰生物跌2.42%，荣昌生物跌3.43%。三生制药是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，业务覆盖血小板减少症、慢性肾病贫血症、强直性脊柱炎等领域，同时从事CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651289171","title":"【券商聚焦】中信证券：预计美妆行业在次季延续低速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2651289171","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651289171?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:55","pubTimestamp":1783990545,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，22026Q2，预计美妆行业在需求疲弱、流量成本走高、内容运营压力加大的背景下延续低速增长；结构性进一步分化，国际高端品牌销售反弹，本土大众、中端定位品牌承压；毛戈平、林清轩延续高增长，巨子生物、贝泰妮、敷尔佳销售底部回升。2026Q2，医美板块上游产品供给增加，竞争延续较高强度，四环医药受益于自主产品上市继续提升市场份额。估值已充分反映当前的经营压力且已严重低估，静候基本面改善和估值回升。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985765","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","LU2488822045.USD","01530","LU1997244956.HKD","BK0276","01696","LU1064131003.USD","LU1328615791.USD","SG9999004311.SGD","BK1521","BK1100","LU1794554557.SGD","06699","00460","BK1564","BK1600","LU2289578879.USD","BK1161","LU1655091616.SGD","LU2148510915.USD","LU1720050803.USD","BK0196","BK0028","LU2495084118.USD","02138","02367","BK1207","BK1215","BK1583","BK1515","LU1997245177.USD","BK1587","BK0012","02373","BK1147","LU0405327148.USD","LU1255011170.USD","LU1580142542.USD","HK0000165453.HKD","LU1997245094.SGD","BK1585","BK0183","02196","06030","LU0405327494.USD","BK1511","BK1516","KCE","LU1064130708.USD","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136482764","title":"异动解读｜三生制药盘中上涨5.53%，报17.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136482764","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136482764?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:46","pubTimestamp":1783651599,"startTime":"0","endTime":"0","summary":"7月10日，三生制药盘中上涨5.53%，报17.96港元/股，成交额3.61亿港元。三生制药所在的生物科技行业中，个股普遍走强，其中派格生物医药-B涨39.42%，荣昌生物涨6.47%，康方生物涨4.97%，信达生物涨4.52%，百济神州涨2.58%。三生制药是一家集研发、生产和销售为一体的生物制药企业，主要产品包括特比澳、益比奥、益赛普等生物药物，业务覆盖血小板减少症、慢性肾病贫血症、强直性脊柱炎等领域，同时从事CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954218","title":"创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954218","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649954218?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:08","pubTimestamp":1783480087,"startTime":"0","endTime":"0","summary":"有研究指，创新药板块年内曾两轮短期反弹，本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑，但机构表示当前仅为估值修复行情，基本面全面反转仍需中期、三季度财报验证，后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","KURE","LU1880383366.USD","159992","09926","02359","IBBQ","LU0052750758.USD","01672","02269","IE00B0JY6N72.USD","LU2242644610.SGD","BK1600","LU0348784397.USD","LU0417516571.SGD","SG9999002463.SGD","LU3063872942.SGD","LU0320764599.SGD","LU0456846285.SGD","LU0326950275.SGD","LU0979878070.USD","BK1521","01477","BK1191","LU0516423091.SGD","LU0819121731.USD","06955","LU0516422440.USD","SG9999014674.SGD","LU2476274308.USD","01952","CZA","MEDX","BK1141","BK1583","LU0572944931.SGD","BK1515","01530","LU0140636845.USD","00460","LU0196878994.USD","06990","LU1046422090.SGD","02186","REVS","LU0348783233.USD","06855","02268","06978","LU0051755006.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176418447","title":"异动解读｜三生制药盘中下跌5.24%，报18.45港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176418447","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176418447?lang=zh_cn&edition=full","pubTime":"2026-07-07 13:56","pubTimestamp":1783403760,"startTime":"0","endTime":"0","summary":"7月7日，三生制药盘中下跌5.24%，报18.45港元/股，成交额3.78亿港元。三生制药所在的生物科技行业中，个股普遍承压，其中荣昌生物跌6.49%，康方生物跌4.66%，信达生物跌3.59%，百济神州跌2.83%，科伦博泰生物跌2.48%。三生制药是一家集研发、生产和销售为一体的生物制药企业，主要产品包括特比澳、益比奥、益赛普等生物药物，业务覆盖血小板减少症、慢性肾病贫血症、强直性脊柱炎等领域，同时从事CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":0.0349},{"period":"1month","weight":0.0375},{"period":"3month","weight":-0.0974},{"period":"6month","weight":-0.2289},{"period":"1year","weight":-0.4195},{"period":"ytd","weight":-0.2538}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006634},{"month":2,"riseRate":0.454545,"avgChangeRate":0.001777},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113184},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080953},{"month":6,"riseRate":0.727273,"avgChangeRate":0.025359},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.034677},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.007589},{"month":9,"riseRate":0.636364,"avgChangeRate":0.027477},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018318},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059928},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045348}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}